Roger's 1998 Short Picks Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bob Trocchi who wrote (9596)	6/3/1998 2:19:00 PM
From: Ploni	Read Replies (3) of 18691

Zonagen Inc. (ZONA) fell as much as 5 1/4 to 31 1/2 as the human reproductive-system specialty drugmaker's test results for its Vasomax impotence treatment were said by analyst Steve Lisi of Mehta Partners to be close to the 20 percent rate reported in the placebo group. I just don't get it. This was widely known; what difference does it make that now it was announced by Steve Lisi? Why does Lisi carry more weight than Asensio, Bill Wexler, and the others who understood this was a generic drug ineffective for erectile disfunction? Also, why does Lisi's bad press override the good press reported by CNBC and ABC news, "that Vasomax is well-tolerated without the side effects of Viagra?" Can someone explain how this market operates to me, because I don't have a clue.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next